Two years af­ter a refuse-to-file, Y-mAbs lands an FDA ad­comm for its 2nd neu­rob­las­toma treat­ment

Y-mAbs Ther­a­peu­tics is look­ing to cap­i­tal­ize on a sec­ond chance at win­ning ap­proval for its po­ten­tial treat­ment of pe­di­atric neu­rob­las­toma with CNS/cere­brospinal flu­id can­cer as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER